Effectiveness, pharmacokinetics, and safety of triptorelin acetate microspheres in patients with locally advanced and metastatic prostate cancer
Background: A newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed. Objectives: To evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese patients with prostate cancer. Design: An open-label, multicente...
Saved in:
| Main Authors: | Guolan Wu, Feng Zhou, Haiping Wang, Kan Liu, Dexin Yu, Lianlian Fan, Yangyun Han, Xiaohong Ai, Youhan Cao, Xiaolin Wang, Sheng Wang, Chaohong He, Jitao Wu, Ji Wu, Youlei Wang, Yanqing Wang, Baiye Jin, Jianzhong Shentu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241307818 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of leuprolide acetate versus triptorelin pamoate administered every 3 months for treatment of central precocious puberty
by: Thanaporn Thaneetrakool, et al.
Published: (2025-01-01) -
Central Precocious Puberty: Treatment with Triptorelin 11.25 mg
by: Elena Chiocca, et al.
Published: (2012-01-01) -
Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China
by: Chen Y, et al.
Published: (2024-12-01) -
Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer
by: Changde Fu, et al.
Published: (2025-03-01) -
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01)